Anders Lindblad

Anders Lindblad

Auto-generated profile, based on publicly available information

Anders Lindblad

Queen Silvia Children's Hospital, Gothenburg, Sweden

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
PWPEter Witters
PEter Witters
LLLouis Libbrecht
Louis Libbrecht
TRTania Roskams
Tania Roskams
KBKris De Boeck
Kris De Boeck
LDLieven Dupont
Lieven Dupont
DCDavid Cassiman
David Cassiman

1 July 2021 in Journal of Applied Physiology
Verified
Journal Article
Closed access
PDF file
RSRikke M. Sandvik
Rikke M. Sandvik
PGPer M. Gustafsson
Per M. Gustafsson
ALAnders Lindblad
Anders Lindblad
PRPaul D Robinson
Paul D Robinson
KNKim G. Nielsen
Kim G. Nielsen
Modern nitrogen multiple-breath washout (N2MBW) systems such as EXHALYZER D use O2 and CO2 sensors to calculate N2 concentrations. New corrections for interactions between high O2 and CO2 concentrations on the gas sensors now provide accurate N2 signals. The correct N2 signal led to much improved agreement between N2MBW and sulfur hexafluoride (SF6) MBW functional residual capacity (FRC) and lung clearance index (LCI) in 52 sleeping healthy infants and toddlers, suggesting a role for N2MBW in this age-group.

28 August 2022 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
AOAnnalisa Orenti
Annalisa Orenti
MMMeir Mei-Zahav
Meir Mei-Zahav
PBPatrizia Boracchi
Patrizia Boracchi
ALAnders Lindblad
Anders Lindblad
MSMichal Shteinberg
Michal Shteinberg

2 February 2023 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
CCCarla Colombo
Carla Colombo
GRGrant A Ramm
Grant A Ramm
ALAnders Lindblad
Anders Lindblad
FCFabiola Corti
Fabiola Corti
LPLUIGI PORCARO
LUIGI PORCARO
GAGianfranco Alicandro
Gianfranco Alicandro

4 July 2025 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
TLTim Lee
Tim Lee
KHKate Hill
Kate Hill
DCDaan Caudri
Daan Caudri
Pierluigi CietPierluigi Ciet
Pierluigi Ciet
GDGwyneth Davies
Gwyneth Davies
HJHettie Mathilde Janssens
Hettie Mathilde Janssens
Cystic fibrosis is a lifelong progressive disease in which lung disease is the main prognostic factor, where starting early treatment is crucial for improving long-term outcomes. Therefore, new treatment should be available as early as possible. However, choosing appropriate and feasible clinical trial endpoints in children under 2 years of age presents significant challenges. Most studies in this age group have extrapolated pulmonary efficacy from older age groups, focusing on safety, pharmacokinetics, and biomarker response. As lung health is near normal in infants, demonstrating absence of pulmonary decline requires large sample sizes and extended study duration, which may not be feasible for standard regulatory trials. To address this gap, the European Cystic Fibrosis Society Clinical Trials Network developed a consensus document evaluating direct pulmonary endpoints for therapeutic pulmonary studies in this young age group. The pulmonary endpoints evaluated include multiple-breath washout (MBW); chest computed tomography (CT); chest magnetic resonance imaging (MRI); airway infection and inflammation. Relevant literature, pitfalls, practice guidelines, and recommendations are presented. None of the pulmonary endpoints evaluated are currently suitable to serve as a primary efficacy endpoint in children below 2 years of age, as this will require large numbers and long follow-up. For clinical trials in infants with CF, pharmacokinetics, pharmacodynamics, safety and tolerability should remain the primary endpoints, with pulmonary endpoints as secondary or exploratory outcomes. Post authorization studies are essential to evaluate long-term pulmonary benefits, including MBW, structural lung assessment (e.g. CT and MRI), and markers of pulmonary inflammation to fully understand the impact of early therapy initiation in this young population.

1 January 1998
Verified
Book Chapter
Closed access
PDF file
TET. Edgren
T. Edgren
ALA. Lindblad
A. Lindblad
SNS. Nordlund
S. Nordlund